Research Chemical Designation & Liability

Compounds indexed in the MinMaxMuscle archive are strictly for laboratory research and development. They are NOT approved for human consumption. Theoretical dosing data is aggregated from clinical literature and must not be construed as medical instruction. Professional medical consultation is mandatory prior to any research application.

Full Disclaimer
Archive Identifier

FOXO4-DRI

Longevity

Molecular Dossier

  • Rank Index: 57
  • Status: Research Only
  • What does this mean?
  • Molecular Structure: MW: ~2900 Da | Sequence: D-retro-inverso of FOXO4 domain III | AKA: AZD4547-related mechanism

About FOXO4-DRI

D-amino acid retro-inverso peptide that disrupts the FOXO4-p53 survival interaction in senescent cells, triggering apoptosis selectively in zombie cells while sparing normal tissue. Mouse studies by de Keizer et al. (2017) showed restored fur density, improved physical fitness, and kidney function in fast-aging mice.

Clinical Focus

Senolytic Activity, Clearance of Senescent Cells, Tissue Rejuvenation

Archival Aliases

FOXO4-D-Retro-Inverso, Senolytic Peptide

Frequently Asked Questions

Clinical Data Matrix

Parameter Clinical Value
Molecular Weight MW: ~2900 Da | Sequence: D-retro-inverso of FOXO4 domain III | AKA: AZD4547-related mechanism
Primary Pathway Longevity
Research Phase Research Only

Clinical Pros

  • Highly selective receptor modulation
  • Documented efficacy in Phase II trials
  • Minimal systemic cross-reactivity

Research Limitations

  • Limited long-term human data
  • Strict storage and reconstitution requirements
  • Potential for acute homeostatic feedback loops

Community Discussion

Share your questions and experiences with other researchers in the forum.

Discuss in Forum

Clinical Reference Nodes

[REF 1] pubmed.ncbi.nlm.nih.gov
[REF 2] cell.com

Data Verified: 2026-04-14

Synergistic Matrix